BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced Phase 1 and Phase 2 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520, at the 2011 Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. These data indicate that ARRY-520 has shown preliminary clinical activity in heavily pre-treated patients with multiple myeloma (MM) and was generally well tolerated. The posters are summarized below and PDF versions are available for download on Array's website at www.arraybiopharma.com.
